Side-by-side · Research reference
BronchogenvsGHRP-6
Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.
AAnimal-StrongHUMAN-REVIEWED16/35 cited
BPhase 1HUMAN-REVIEWED10/36 cited
Bronchogen
Tetrapeptide Bioregulator · Khavinson-School
Research models: tissue culture / parenteral
GHRP-6
Hexapeptide GHRP · Strong appetite stimulant
SQ · Multiple sites · 1–3×/day
01Mechanism of Action
Parameter
Bronchogen
GHRP-6
Pathway
Tissue-specific bioregulation → epithelial cell differentiation → ciliated cell restoration
GHS-R1a → Gαq → Ca²⁺ → GH release; central appetite driveBowers 2002
Downstream effect
Reversal of goblet cell hyperplasia, squamous metaplasia elimination, restoration of ciliated epithelium, normalized secretory IgA and surfactant protein B productionKuzubova 2015Titova 2017
GH pulse + strong appetite stimulation; modest IGF-1 elevationBowers 2002
Feedback intact?
—
—
Origin
Synthetic tetrapeptide (Ala-Glu-Asp-Leu) from Khavinson bioregulator framework
Synthetic hexapeptide; first-generation GHRP from Bowers groupBowers 1990
Antibody development
—
—
02Dosage Protocols
Parameter
Bronchogen
GHRP-6
Effective concentration (culture)
0.05 ng/mLZakutskiĭ 2006
Demonstrated in organotypic tissue culture of bronchial explants.
—
Treatment duration (animal)
1 month (30 days)Kuzubova 2015Titova 2017
Course duration in rat COPD models.
—
Evidence basis
Animal models (rat) / organotypic cultureTitova 2017Kuzubova 2015Zakutskiĭ 2006
No human clinical trials reported in available literature.
Phase 1 + clinical practiceBowers 1990
Tissue specificity
Selective for bronchopulmonary tissue
Part of Khavinson organ-specific bioregulator series.
—
Frequency
—
1–3× per day
Lower / starter dose
—
50 mcg per dose
Duration
—
8–12 weeks on / 4 off
Reconstitution
—
Bacteriostatic water
Timing
—
Pre-meal preferred for appetite support
04Side Effects & Safety
Parameter
Bronchogen
GHRP-6
Animal safety profile
No adverse effects reported in published rat studies
Limited safety data; only animal models available.
—
Human data
Absent — no clinical trials in humans reported
—
Long-term effects
Unknown — maximum study duration 30 days in animals
—
Hunger
—
Pronounced — defining feature vs ipamorelin
Cortisol elevation
—
Mild
Prolactin elevation
—
Mild
Injection site reaction
—
Mild
Cancer risk
—
Contraindicated in active malignancy
Pregnancy / OB
—
Avoid
Absolute Contraindications
Bronchogen
—GHRP-6
- ·Active malignancy
- ·Pregnancy / breastfeeding
Relative Contraindications
Bronchogen
—GHRP-6
- ·Severe insulin resistance (appetite-driven caloric load)
05Administration Protocol
Parameter
Bronchogen
GHRP-6
1. Research context only
Bronchogen has been studied exclusively in animal models and organotypic tissue culture. No approved formulation or human administration protocol exists.
Add 2 mL bacteriostatic water to 5 mg vial → 2.5 mg/mL.
2. Animal model protocol
In rat COPD models, tetrapeptide administered for 30-day course following 60-day NO₂ exposure. Route and exact dosing not specified in abstracts.Titova 2017Kuzubova 2015
SQ — abdomen. Rotate sites.
3. Organotypic culture
Bronchial tissue explants from young (3-week) and aged (18-month) rats cultured in medium containing 0.05 ng/mL bronchogen, demonstrating tissue-specific stimulation.Zakutskiĭ 2006
Pre-meal for appetite support; pre-sleep for GH alignment.
4. Khavinson bioregulator tradition
Part of Russian peptide bioregulator framework emphasizing tissue-specific low-dose effects. Typically administered parenterally in related peptides from this series.
Lyophilised: room temp. Reconstituted: refrigerate ≤30 days.
5. Needle
—
29–31G, 4–8 mm insulin syringe.